StockMarketWire.com - Bio-marker group Oxford BioDynamics noted that its technology had been used in a medical study, the results of which were published in the peer-reviewed journal EBioMedicine.

In the study, the company's EpiSwitch platform was used to compare the genomic architecture of healthy and ayotrophic lateral sclerosis patient samples to discover an epigenetic bio-marker.

The study successfully yielded a distinct bio-marker that was diagnostic for the condition, demonstrating a highly-promising, potential new approach to the diagnosis of the disease, Oxford BioDynamics said.


At 9:46am: [LON:OBD] Oxford Biodynamics Plc share price was 0p at 212p



Story provided by StockMarketWire.com